UMIN ID: UMIN000016583
Registered date:26/02/2015
ZELBORAF Special Drug Use Surveillance (Malignant Melanoma)
Basic Information
| Recruitment status | Recruiting |
|---|---|
| Health condition(s) or Problem(s) studied | Malignant Melanoma |
| Date of first enrollment | 2015/02/26 |
| Target sample size | 500 |
| Countries of recruitment | Japan |
| Study type | Observational |
| Intervention(s) |
Outcome(s)
| Primary Outcome | Adverse reaction incidence |
|---|---|
| Secondary Outcome | Effectiveness OS |
Key inclusion & exclusion criteria
| Age minimum | Not applicable |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | No criteria |
Related Information
| Primary Sponsor | Chugai Pharmaceutical Co. Ltd. |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Chugai Pharmaceutical Co. Ltd. |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Ryousuke Harada |
| Address | 1-1 Nihonbashi-muromachi 2-chome, Chuo-ku Tokyo, Japan Japan 103-8324 |
| Telephone | 03-3281-6611 |
| haradarus@chugai-pharm.co.jp | |
| Affiliation | Chugai Pharmaceutical Co. Ltd. Safety science Dept |
| scientific contact | |
| Name | Nomura Makoto |
| Address | 1-1 Nihonbashi-muromachi 2-chome, Chuo-ku Tokyo, Japa Japan |
| Telephone | 03-3281-6611 |
| nomuramkt@chugai-pharm.co.jp | |
| Affiliation | Chugai Pharmaceutical Co. Ltd. Safety science Dept |